Journals / Middle Black Sea Journal of Health Science / 2015 / Cilt: 1 - Sayı: 3

Correlation of Platelet to Lymphocyte Ratio with Presence and Severity of Metabolic Syndrome

Pages
18–24
Publication Date
2015-12-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

PLR may be beneficial in predicting the adverse cardiovascular cases in the patients with MS.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study is to evaluate the relation between the components of Metabolic syndrome (MS) and the inflammation and the platelet-to-lymphocyte ratio (PLR) recognized as a novel marker of pro-thrombotic state.Method: 70 patients with MS criteria were included in the study. 70 healthy people with matching age and gender characteristics were included in the study as the control group.
📊
Key Findings & Data:The patients were divided into three groups with regard to the number of MS characteristics: Group 1 (the patients with three MS criteria), group 2 (the patients with four MS criteria), and group 3 (the patients with five MS criteria).
💡
Conclusion & Impact:PLR may be beneficial in predicting the adverse cardiovascular cases in the patients with MS.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Metabolic Syndrome · Platelet/lymphocyte ratio · Inflammation

Abstract

Objective: The aim of this study is to evaluate the relation between the components of Metabolic syndrome (MS) and the inflammation and the platelet-to-lymphocyte ratio (PLR) recognized as a novel marker of pro-thrombotic state.Method: 70 patients with MS criteria were included in the study. 70 healthy people with matching age and gender characteristics were included in the study as the control group. The patients were divided into three groups with regard to the number of MS characteristics: Group 1 (the patients with three MS criteria), group 2 (the patients with four MS criteria), and group 3 (the patients with five MS criteria). PLR was calculated in regard to the complete blood count.Results: The patients with MS had significantly higher PLR level compared to those without MS. However, PLR level were not associated with severity of MS. A moderate positive correlation was revealed between the severity of MS and PLR (r=0.419, p<0.001) and a strong positive correlation between the severity of MS and hs-CRP (r=0.562, p<0.001). Also, a positive correlation was detected between hs-CRP and PLR in our patient population (r=0.281, p=0.002). In order to specify the level of PLR to predict MS, ROC curve analysis was performed. The cut-off level for PLR with optimal sensitivity and specificity was calculated as 0,132 (Area under curve [AUC] =0.744 [0.655-0.833], p<0.001). For that level, the sensitivity was 73% and the specificity was 68, 4%.Conclusion: This is the first study which determines the fact that there is a relation between MS criteria, the inflammation and PLR, which is a new marker of the pro-thrombotic state. There is also a positive correlation between PLR and hs-CRP in these patients. PLR may be beneficial in predicting the adverse cardiovascular cases in the patients with MS.

🔖

Cite This Article

Kaya, Y., Bektaş, O., Kaya, A., Günaydın, Z., Bayramoğlu, A., Çalgın, M. (2015). Correlation of Platelet to Lymphocyte Ratio with Presence and Severity of Metabolic Syndrome. Middle Black Sea Journal of Health Science, Cilt: 1 - Sayı: 3, 18–24. https://ajindex.com/articles/790124

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. References: Bloomgarden ZT. American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome. Diabetes Care. 2003;26:1297-303.
  2. Hori Y, Nakatani K, Morioka K, et al. Insulin enhanced thrombin-activable fibrinolysis inhibitor expression through PI3 kinase/Akt pathway. Int J Mol Med.2005;15:265-8.
  3. Calles-Escandon J, Mirza SA, Sobel BE, et al. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes.1998;47:290-3.
  4. Yudkin JS, Stehouwer CD, Emesis JJ, et al. C-reactive protein in healthy subjects; associations with obesity, insulin resistance, and endothelial dysfunction. Arterioscler Thromb Vasc Biol.1999;19: 972-8. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med.2005;352:1685-95.
  5. Smith RA, Ghaneh P, Sutton R, et al. Prognosis of resected ampullary adenocarcinoma by preoperative serum CA199 levels and platelet-lymphocyte ratio. J Gastrointest Surg.2008;12:1422-8.
  6. Wang D, Yang JX, Cao DY, et al. Preoperative neutrophil-lymphocyte and platelet-lymphocyte ratios as independent predictors of cervical stromal involvement in surgically treated endometrioid adenocarcinoma. Onco Targets Ther. 2013;6:211-6.
  7. Azab B, Shah N, Akerman M, et al. Value of platelet/lymphocyte ratio as a predictor of all-cause mortality after non-ST-elevation myocardial infarction. J Thromb Thrombolysis. 2012;34:326-34.
  8. Acar G, Kalkan ME, Avci A, et al. The Relation of Platelet-Lymphocyte Ratio and Coronary Collateral Circulation in Patients With Stable Angina Pectoris and Chronic Total Occlusion. Clin Appl Thromb Hemost. 2013;doi: 10.1177/1076029613508599 Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on the Detection, Diagnosis, and Treatment of High Cholesterol in Adults: (Adult Treatment Panel III). JAMA. 2001; 285: 2486-97.
  9. Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol.2004;44:2293-300.
  10. Fröhlich M, Imhof A, Berg G, et al. Association between C-reactive protein and features of the metabolic syndrome. Diabetes Care. 2000; 23: 1835-9.
  11. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events. Circulation. 2003; 107: 391-7. Haffner SM. The metabolic syndrome: Inflammation, diabetes mellitus, and cardiovascular disease. Am